Symbols / AYTU
AYTU Chart
About
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 24.79M |
| Enterprise Value | 16.44M | Income | -24.56M | Sales | 62.64M |
| Book/sh | 1.32 | Cash/sh | 2.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 82 | IPO | — |
| P/E | — | Forward P/E | 13.59 | PEG | — |
| P/S | 0.40 | P/B | 1.75 | P/C | — |
| EV/EBITDA | 4.08 | EV/Sales | 0.26 | Quick Ratio | 0.93 |
| Current Ratio | 1.16 | Debt/Eq | 155.63 | LT Debt/Eq | — |
| EPS (ttm) | -3.44 | EPS next Y | 0.17 | EPS Growth | — |
| Revenue Growth | -6.50% | Earnings | 2026-02-03 16:00 | ROA | -0.22% |
| ROE | -109.23% | ROIC | — | Gross Margin | 66.84% |
| Oper. Margin | -12.99% | Profit Margin | -39.02% | Shs Outstand | 10.73M |
| Shs Float | 7.61M | Short Float | 5.95% | Short Ratio | 4.39 |
| Short Interest | — | 52W High | 3.07 | 52W Low | 0.95 |
| Beta | 0.36 | Avg Volume | 94.26K | Volume | 11.04K |
| Target Price | $9.33 | Recom | None | Prev Close | $2.27 |
| Price | $2.31 | Change | 1.76% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.33
Mean price target
2. Current target
$2.27
Latest analyst target
3. DCF / Fair value
$-11.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.27
Low
$7.00
High
$13.00
Mean
$9.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-10 | main | Ascendiant Capital | Buy → Buy | $13 |
| 2025-09-25 | main | Maxim Group | Buy → Buy | $7 |
| 2025-09-25 | main | Ascendiant Capital | Buy → Buy | $13 |
| 2025-07-01 | init | Lake Street | — → Buy | $8 |
| 2025-06-30 | init | Ascendiant Capital | — → Buy | $12 |
| 2023-08-09 | init | Maxim Group | — → Buy | $5 |
| 2023-05-31 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
- Positive Signs As Multiple Insiders Buy Aytu BioPharma Stock - Yahoo Finance Fri, 21 Nov 2025 08
- Depression drug EXXUA takes center stage at New York investor event - Stock Titan hu, 18 Dec 2025 08
- Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st Sat, 20 Dec 2025 08
- Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline - Sahm hu, 05 Feb 2026 08
- New Strong Sell Stocks for February 2nd - Nasdaq Mon, 02 Feb 2026 08
- New Analyst Forecast: $AYTU Given $13 Price Target | AYTU Stock News - Quiver Quantitative Wed, 10 Dec 2025 08
- Earnings call transcript: Aytu BioPharma’s Q1 2025 shows stable stock - Investing.com hu, 13 Nov 2025 08
- Armistice Capital Overcomes Novel Ruling in Aytu Stock Case (1) - Bloomberg Law News hu, 14 Aug 2025 07
- Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - ACCESS Newswire ue, 27 Jan 2026 08
- Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance ue, 03 Feb 2026 08
- Aytu BioPharma (Nasdaq: AYTU) makes EXXUA depression drug commercially available in US - Stock Titan Mon, 15 Dec 2025 08
- Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Yahoo Finance hu, 05 Feb 2026 08
- New depression drug EXXUA avoids sexual dysfunction and weight gain - Stock Titan ue, 20 Jan 2026 08
- Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Path To Profitability - Yahoo Finance Sun, 17 Aug 2025 07
- New EXXUA depression drug targets MDD without sexual side effects - Stock Titan ue, 20 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | LIU VIVIAN H | Director | — | 2025-10-03 00:00:00 | D |
| 1 | 53946 | — | — | Stock Award(Grant) at price 0.00 per share. | DISBROW JOSHUA R. | Chief Executive Officer | — | 2025-10-03 00:00:00 | D |
| 2 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | DOCKERY CARL C | Director | — | 2025-10-03 00:00:00 | D |
| 3 | 32106 | — | — | Stock Award(Grant) at price 0.00 per share. | DISBROW JARRETT T | Officer | — | 2025-10-03 00:00:00 | D |
| 4 | 33743 | — | — | Stock Award(Grant) at price 0.00 per share. | SELHORN RYAN J | Chief Financial Officer | — | 2025-10-03 00:00:00 | D |
| 5 | 12500 | — | — | Stock Award(Grant) at price 0.00 per share. | PYSZCZYMUKA GREG | Officer | — | 2025-10-03 00:00:00 | D |
| 6 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | JAIN ABHINAV | Director | — | 2025-10-03 00:00:00 | D |
| 7 | 66666 | 140665.0 | — | Purchase at price 2.11 per share. | DISBROW JOSHUA R. | Chief Executive Officer | — | 2025-06-09 00:00:00 | D |
| 8 | 16666 | 35165.0 | — | Purchase at price 2.11 per share. | DISBROW JARRETT T | Officer | — | 2025-06-09 00:00:00 | D |
| 9 | 209 | nan | — | — | PYSZCZYMUKA GREG | Officer | — | 2025-03-31 00:00:00 | D |
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -2.53M | -1.42M | 0.00 | -64.83K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | 7.40M | 8.16M | -3.33M | 46.07M |
| TotalUnusualItems | -12.07M | -6.75M | 57.00K | -72.03M |
| TotalUnusualItemsExcludingGoodwill | -12.07M | -6.75M | 57.00K | -72.03M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.18M | -12.52M | -17.05M | -108.78M |
| ReconciledDepreciation | 5.38M | 6.72M | 8.81M | 10.15M |
| ReconciledCostOfRevenue | 18.86M | 13.09M | 36.74M | 40.08M |
| EBITDA | -4.67M | 1.41M | -3.27M | -25.96M |
| EBIT | -10.04M | -5.32M | -12.09M | -36.10M |
| NetInterestIncome | -3.70M | -5.06M | -4.96M | |
| InterestExpense | 3.70M | 5.06M | 4.96M | |
| NormalizedIncome | -4.65M | -7.18M | -17.11M | -36.81M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.56M | -15.84M | -17.05M | -108.78M |
| TotalExpenses | 63.84M | 64.62M | 119.73M | 132.77M |
| TotalOperatingIncomeAsReported | -7.83M | -1.59M | -17.07M | -109.91M |
| DilutedAverageShares | 6.28M | 5.54M | 3.34M | 1.47M |
| BasicAverageShares | 6.28M | 5.54M | 3.34M | 1.47M |
| DilutedEPS | -2.16 | -2.86 | -5.11 | -75.00 |
| BasicEPS | -2.16 | -2.86 | -5.11 | -75.00 |
| DilutedNIAvailtoComStockholders | -13.56M | -15.84M | -17.05M | -108.78M |
| NetIncomeCommonStockholders | -13.56M | -15.84M | -17.05M | -108.78M |
| NetIncome | -13.56M | -15.84M | -17.05M | -108.78M |
| NetIncomeIncludingNoncontrollingInterests | -13.56M | -15.84M | -17.05M | -108.78M |
| NetIncomeDiscontinuousOperations | 620.00K | -3.32M | ||
| NetIncomeContinuousOperations | -14.18M | -12.52M | -17.05M | -108.78M |
| TaxProvision | 437.00K | 2.14M | 0.00 | -110.00K |
| PretaxIncome | -13.74M | -10.38M | -17.05M | -108.89M |
| OtherIncomeExpense | -12.58M | -5.88M | 241.00K | -72.79M |
| OtherNonOperatingIncomeExpenses | -512.00K | 870.00K | 184.00K | -757.00K |
| SpecialIncomeCharges | -10.36M | -2.75M | -4.74M | -73.63M |
| OtherSpecialCharges | 594.00K | -169.00K | 1.57M | |
| WriteOff | 8.26M | 0.00 | 5.71M | 9.66M |
| ImpairmentOfCapitalAssets | 0.00 | 65.80M | 12.82M | |
| RestructuringAndMergernAcquisition | 2.10M | 2.16M | -969.00K | -1.66M |
| GainOnSaleOfSecurity | -1.70M | -4.00M | 4.79M | 1.60M |
| NetNonOperatingInterestIncomeExpense | -3.70M | -5.06M | -4.96M | |
| InterestExpenseNonOperating | 3.70M | 5.06M | 4.96M | |
| OperatingIncome | 2.54M | 565.00K | -12.33M | -36.10M |
| OperatingExpense | 43.29M | 48.49M | 78.96M | 88.39M |
| DepreciationAmortizationDepletionIncomeStatement | 3.68M | 3.68M | 4.79M | 5.84M |
| DepreciationAndAmortizationInIncomeStatement | 3.68M | 3.68M | 4.79M | 5.84M |
| Amortization | 3.68M | 3.68M | 4.79M | 5.84M |
| AmortizationOfIntangiblesIncomeStatement | 3.68M | 3.68M | 4.79M | 5.84M |
| ResearchAndDevelopment | 1.33M | 2.77M | 4.09M | 12.66M |
| SellingGeneralAndAdministration | 38.28M | 42.04M | 70.08M | 69.88M |
| SellingAndMarketingExpense | 20.91M | 22.08M | 41.45M | 38.71M |
| GeneralAndAdministrativeExpense | 17.38M | 19.95M | 28.63M | 31.17M |
| OtherGandA | 17.38M | 19.95M | 28.63M | 31.17M |
| GrossProfit | 45.83M | 49.05M | 66.63M | 52.28M |
| CostOfRevenue | 20.55M | 16.13M | 40.77M | 44.39M |
| TotalRevenue | 66.38M | 65.18M | 107.40M | 96.67M |
| OperatingRevenue | 66.38M | 65.18M | 107.40M | 96.67M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 8.98M | 5.97M | 5.52M | 1.93M |
| ShareIssued | 8.98M | 5.97M | 5.52M | 1.93M |
| TotalDebt | 21.82M | 15.13M | 16.36M | 18.19M |
| TangibleBookValue | -23.23M | -24.74M | -19.61M | -26.32M |
| InvestedCapital | 40.78M | 42.84M | 55.72M | 62.50M |
| WorkingCapital | 16.11M | -337.00K | 2.06M | -4.51M |
| NetTangibleAssets | -23.23M | -24.74M | -19.61M | -26.32M |
| CapitalLeaseObligations | 3.56M | |||
| CommonStockEquity | 18.97M | 27.72M | 39.36M | 44.31M |
| TotalCapitalization | 29.86M | 38.59M | 54.07M | 58.59M |
| TotalEquityGrossMinorityInterest | 18.97M | 27.72M | 39.36M | 44.31M |
| StockholdersEquity | 18.97M | 27.72M | 39.36M | 44.31M |
| RetainedEarnings | -333.54M | -319.97M | -304.13M | -287.08M |
| AdditionalPaidInCapital | 352.50M | 347.69M | 343.49M | 331.39M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 0.00 |
| CommonStock | 1.00K | 1.00K | 1.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 105.21M | 90.38M | 97.11M | 93.31M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 42.15M | 28.15M | 28.09M | 28.87M |
| OtherNonCurrentLiabilities | 4.92M | 4.53M | 6.97M | 12.80M |
| DerivativeProductLiabilities | 26.33M | 12.74M | 6.40M | 1.80M |
| LongTermDebtAndCapitalLeaseObligation | 10.89M | 10.88M | 14.71M | 14.28M |
| LongTermCapitalLeaseObligation | 2.62M | |||
| LongTermDebt | 10.89M | 10.88M | 14.71M | 14.28M |
| CurrentLiabilities | 63.06M | 62.23M | 69.02M | 64.44M |
| OtherCurrentLiabilities | 3.38M | 9.52M | 7.09M | 5.36M |
| CurrentDebtAndCapitalLeaseObligation | 10.92M | 4.25M | 1.65M | 3.91M |
| CurrentCapitalLeaseObligation | 940.00K | |||
| CurrentDebt | 10.92M | 4.25M | 1.65M | 3.91M |
| OtherCurrentBorrowings | 1.86M | 1.86M | 85.00K | 96.00K |
| LineOfCredit | 9.06M | 2.40M | 1.56M | 3.81M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.13M | 4.60M | 5.67M | 4.76M |
| CurrentProvisions | 6.81M | 4.83M | 5.78M | 5.77M |
| PayablesAndAccruedExpenses | 38.82M | 39.02M | 48.83M | 44.64M |
| CurrentAccruedExpenses | 28.22M | 28.71M | 35.35M | 33.65M |
| Payables | 10.60M | 10.31M | 13.48M | 10.99M |
| AccountsPayable | 10.60M | 10.31M | 13.48M | 10.99M |
| TotalAssets | 124.18M | 118.09M | 136.46M | 137.62M |
| TotalNonCurrentAssets | 45.00M | 56.20M | 65.38M | 77.69M |
| OtherNonCurrentAssets | 1.20M | 2.23M | 2.54M | 766.00K |
| GoodwillAndOtherIntangibleAssets | 42.20M | 52.45M | 58.97M | 70.63M |
| OtherIntangibleAssets | 42.20M | 52.45M | 58.97M | 70.63M |
| Goodwill | 0.00 | 65.80M | ||
| NetPPE | 1.59M | 1.52M | 3.87M | 6.30M |
| AccumulatedDepreciation | -714.00K | -2.12M | -3.68M | -2.42M |
| GrossPPE | 2.31M | 3.65M | 7.55M | 8.72M |
| Leases | 164.00K | 35.00K | 999.00K | 999.00K |
| ConstructionInProgress | 0.00 | 107.00K | 0.00 | 198.00K |
| OtherProperties | 1.87M | 2.67M | 5.32M | 6.59M |
| MachineryFurnitureEquipment | 274.00K | 945.00K | 1.12M | 1.13M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 79.18M | 61.89M | 71.08M | 59.93M |
| OtherCurrentAssets | 5.64M | 5.10M | 7.16M | 8.01M |
| AssetsHeldForSaleCurrent | 0.00 | 1.12M | ||
| RestrictedCash | 0.00 | 252.00K | ||
| PrepaidAssets | 8.05M | 7.38M | 9.78M | |
| Inventory | 11.43M | 12.14M | 11.99M | 10.85M |
| FinishedGoods | 8.94M | 6.15M | 7.74M | 7.20M |
| WorkInProcess | 1.38M | 5.72M | 2.96M | 1.84M |
| RawMaterials | 1.11M | 266.00K | 1.30M | 1.81M |
| Receivables | 31.16M | 23.53M | 28.94M | 21.71M |
| AccountsReceivable | 31.16M | 23.53M | 28.94M | 21.71M |
| AllowanceForDoubtfulAccountsReceivable | -1.19M | -1.82M | -2.99M | 0.00 |
| GrossAccountsReceivable | 32.34M | 25.35M | 31.93M | 21.71M |
| CashCashEquivalentsAndShortTermInvestments | 30.95M | 20.01M | 22.98M | 19.36M |
| CashAndCashEquivalents | 30.95M | 20.01M | 22.98M | 19.36M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -5.17M | -1.72M | -5.13M | -28.82M |
| RepaymentOfDebt | -1.86M | -15.72M | -2.35M | -20.22M |
| IssuanceOfDebt | 8.53M | 13.83M | 0.00 | 15.00M |
| IssuanceOfCapitalStock | 14.84M | 3.47M | 15.57M | 11.69M |
| CapitalExpenditure | -3.23M | -329.00K | ||
| InterestPaidSupplementalData | 2.82M | 4.04M | 3.81M | 3.15M |
| IncomeTaxPaidSupplementalData | 1.42M | 1.61M | 0.00 | |
| EndCashPosition | 30.95M | 20.01M | 22.98M | 19.36M |
| BeginningCashPosition | 20.01M | 22.98M | 19.36M | 49.90M |
| ChangesInCash | 10.95M | -2.98M | 3.62M | -30.54M |
| FinancingCashFlow | 15.44M | -1.26M | 8.87M | 1.53M |
| CashFlowFromContinuingFinancingActivities | 15.44M | -1.26M | 8.87M | 1.53M |
| NetOtherFinancingCharges | -6.07M | -2.84M | -4.36M | -4.94M |
| ProceedsFromStockOptionExercised | 0.00 | |||
| NetCommonStockIssuance | 14.84M | 3.47M | 15.57M | 11.69M |
| CommonStockIssuance | 14.84M | 3.47M | 15.57M | 11.69M |
| NetIssuancePaymentsOfDebt | 6.67M | -1.89M | -2.35M | -5.22M |
| NetShortTermDebtIssuance | 6.67M | 832.00K | -2.25M | -4.12M |
| ShortTermDebtPayments | -2.25M | -4.12M | -53.98M | |
| ShortTermDebtIssuance | 6.67M | 832.00K | 152.24M | 51.21M |
| NetLongTermDebtIssuance | 0.00 | -2.72M | -96.00K | -1.10M |
| LongTermDebtPayments | -1.86M | -15.72M | -96.00K | -16.10M |
| LongTermDebtIssuance | 1.86M | 13.00M | 0.00 | 15.00M |
| InvestingCashFlow | -2.56M | -329.00K | -117.00K | -3.25M |
| CashFlowFromContinuingInvestingActivities | -2.56M | -329.00K | -117.00K | -3.25M |
| NetOtherInvestingChanges | -329.00K | -117.00K | -70.00K | -2.30M |
| NetBusinessPurchaseAndSale | -5.00K | -3.18M | -481.00K | |
| SaleOfBusiness | 0.00 | 15.72M | ||
| PurchaseOfBusiness | -5.00K | -3.18M | -16.20M | |
| NetIntangiblesPurchaseAndSale | -3.00M | 0.00 | ||
| PurchaseOfIntangibles | -3.00M | 0.00 | ||
| NetPPEPurchaseAndSale | 440.00K | -329.00K | ||
| SaleOfPPE | 668.00K | 0.00 | ||
| PurchaseOfPPE | -228.00K | -329.00K | ||
| OperatingCashFlow | -1.94M | -1.39M | -5.13M | -28.82M |
| CashFlowFromContinuingOperatingActivities | -1.94M | -1.39M | -5.13M | -28.82M |
| ChangeInWorkingCapital | -5.73M | -4.66M | -5.80M | -10.86M |
| ChangeInOtherWorkingCapital | 792.00K | 5.87M | -1.87M | 50.00K |
| ChangeInPayablesAndAccruedExpense | 1.17M | -11.24M | 5.99M | -20.97M |
| ChangeInAccruedExpense | 886.00K | -9.16M | 3.60M | -13.29M |
| ChangeInPayable | 287.00K | -2.08M | 2.38M | -7.68M |
| ChangeInAccountPayable | 287.00K | -2.08M | 2.38M | -7.68M |
| ChangeInPrepaidAssets | -451.00K | 329.00K | 846.00K | 2.23M |
| ChangeInInventory | 382.00K | -4.82M | -3.61M | 1.30M |
| ChangeInReceivables | -7.63M | 5.20M | -7.15M | 6.53M |
| ChangesInAccountReceivables | -7.63M | 5.20M | -7.15M | 6.53M |
| OtherNonCashItems | 1.11M | 4.42M | -403.00K | -1.85M |
| StockBasedCompensation | 576.00K | 2.37M | 6.05M | 5.25M |
| ProvisionandWriteOffofAssets | -69.00K | 608.00K | ||
| AssetImpairmentCharge | 8.59M | 1.19M | 8.06M | 77.64M |
| DepreciationAmortizationDepletion | 5.38M | 6.72M | 8.81M | 10.15M |
| DepreciationAndAmortization | 5.38M | 6.72M | 8.81M | 10.15M |
| Depreciation | 5.38M | 6.72M | 8.81M | 10.15M |
| OperatingGainsLosses | 1.70M | 4.40M | -4.79M | -373.00K |
| GainLossOnInvestmentSecurities | 1.70M | 4.00M | -4.79M | -180.00K |
| NetIncomeFromContinuingOperations | -13.56M | -15.84M | -17.05M | -108.78M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AYTU
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|